Free Newsletter
Sea option becoming viable for drug shipments
Trouble is brewing above. Though beleaguered airlines currently have plenty of room for drug cargo--and even appear to be catering to the drug business, as we've reported--they are cutting capacity. As the improving economy re-energizes global commerce in all industries, drug space on aircraft may become hard to find, says Kevin O'Donnell, a director at Tegrant Corp., in Pharmaceutical Commerce magazine.
A dozen vaccines are nearing approval for distribution in developing and middle-income countries, according to the Partnership for Appropriate Technology in Healthcare. And vaccine shipments are getting fatter: PATH projects a five-fold increase in cubic volume for three of these, thanks to the packaging of fewer doses per vial to minimize spoilage. In addition, temperature-sensitive biologics as a whole are growing nicely and projected to represent half of drug approvals by 2015.
These and other elements, when combined, will cause a cargo crunch. "If the airlines move too cautiously, capacity will become an issue," writes O'Donnell. "Even though pharmaceutical freight has a higher priority index than general cargo, there is a real potential that demand could exceed available capacity."
A transport alternative to consider is sea shipment, he says. "While the risk of putting multi-million dollar shipments of brand equity on the waves is not a consideration most pharma companies have entertained in the past, developing technologies for refrigerated sea containers and logistics" makes it worth a second look, according to O'Donnell. He provides a biopharma to-do list to help manufacturers prepare for the coming crunch.
- here's the article
Related Articles:
Cold chain calls to suffering airlines
Booming vax market will more than double by 2014
Vax makers hit a roadblock, slowing global supply
Biologics to top pharma sales by 2014
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

SHARE
WITH: